Gilead Sciences Inc. (GILD) Receives Outperform Rating from Robert W. Baird
Robert W. Baird reiterated their outperform rating on shares of Gilead Sciences Inc. (NASDAQ:GILD) in a research report sent to investors on Tuesday. The brokerage currently has a $100.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $122.00.
A number of other equities research analysts have also recently commented on GILD. Piper Jaffray Cos. set a $108.00 price target on shares of Gilead Sciences and gave the company a buy rating in a report on Sunday, August 21st. Jefferies Group reiterated a hold rating and set a $97.00 price target on shares of Gilead Sciences in a report on Friday, July 15th. Argus cut shares of Gilead Sciences from a buy rating to a hold rating and cut their price target for the company from $88.00 to $81.00 in a report on Friday, July 29th. RBC Capital Markets reiterated an outperform rating and set a $105.00 price target (down previously from $120.00) on shares of Gilead Sciences in a report on Tuesday, July 26th. Finally, Barclays PLC reiterated an overweight rating on shares of Gilead Sciences in a report on Thursday, July 28th. Ten analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $102.78.
Gilead Sciences (NASDAQ:GILD) traded up 0.44% during trading on Tuesday, hitting $73.73. The stock had a trading volume of 1,811,120 shares. The firm has a 50 day moving average price of $77.59 and a 200-day moving average price of $84.05. The firm has a market capitalization of $97.30 billion, a PE ratio of 6.47 and a beta of 1.10. Gilead Sciences has a 1-year low of $72.21 and a 1-year high of $111.11.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.02 by $0.06. The business had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The business’s revenue was down 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.15 earnings per share. On average, equities research analysts expect that Gilead Sciences will post $11.76 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 2.56%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is presently 16.56%.
In other Gilead Sciences news, insider John C. Martin sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $77.63, for a total transaction of $7,763,000.00. Following the sale, the insider now owns 3,231,096 shares of the company’s stock, valued at approximately $250,829,982.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kevin E. Lofton sold 3,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 24th. The stock was sold at an average price of $81.97, for a total transaction of $286,895.00. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors L.L.C. increased its stake in Gilead Sciences by 4.3% in the first quarter. Nisa Investment Advisors L.L.C. now owns 500,421 shares of the biopharmaceutical company’s stock valued at $45,969,000 after buying an additional 20,700 shares in the last quarter. Virginia Retirement System bought a new stake in Gilead Sciences during the first quarter valued at $45,762,000. Tiemann Investment Advisors LLC increased its stake in Gilead Sciences by 14.1% in the first quarter. Tiemann Investment Advisors LLC now owns 4,450 shares of the biopharmaceutical company’s stock valued at $409,000 after buying an additional 550 shares in the last quarter. Dynamic Advisors Solutions LLC increased its stake in Gilead Sciences by 2.1% in the first quarter. Dynamic Advisors Solutions LLC now owns 16,625 shares of the biopharmaceutical company’s stock valued at $1,527,000 after buying an additional 335 shares in the last quarter. Finally, Compton Capital Management Inc. RI increased its stake in Gilead Sciences by 0.9% in the first quarter. Compton Capital Management Inc. RI now owns 66,965 shares of the biopharmaceutical company’s stock valued at $6,151,000 after buying an additional 570 shares in the last quarter. 78.00% of the stock is currently owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.